This study is a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of nuvisertib (TP-3654) in patients with intermediate or high-risk primary or secondary MF.
This study is a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of nuvisertib (TP-3654) in patients with intermediate or high-risk primary or secondary MF.
A Study of Oral Nuvisertib (TP-3654) in Patients with Myelofibrosis
-
University of Alabama, Birmingham, Alabama, United States, 35294
The University of Arizona Cancer Center, Tucson, Arizona, United States, 85724
City of Hope, Duarte, California, United States, 91010
University of Southern California, Los Angeles, California, United States, 90033
Hoag Family Cancer Institute, Newport Beach, California, United States, 92663
Blood Cancer Center, Denver, Colorado, United States, 80218
University of Florida Health Shands Cancer Hospital, Gainesville, Florida, United States, 32608
University of Miami, Miami, Florida, United States, 33136
Emory University, Atlanta, Georgia, United States, 30322
University of Chicago, Chicago, Illinois, United States, 60637
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Sumitomo Pharma America, Inc.,
2030-04-30